Chemical subgroup
N02CD – Calcitonin-Gene-Related-Peptide (CGRP)-Antagonisten
8Decisions
15Patient groups
Added benefit by patient group
- Considerable4
- Not proven11
Decisions, newest first
- 2025-11-20VyduraRimegepantNot proven
- 2025-11-20VyduraRimegepantNot proven: 2 of 2 patient groups
- 2025-08-21AquiptaAtogepantNot proven: 2 of 2 patient groups
- 2023-02-16VyeptiEptinezumabNot proven: 2 of 2 patient groups
- 2021-10-21AimovigErenumabConsiderable
- 2019-11-07AjovyFremanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-09-19EmgalityGalcanezumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-05-02AimovigErenumabConsiderable
Data status: 2026-10-29